The private equity firm Gilde Healthcare has raised a new €100 million fund for supporting the growth of healthcare companies in Belgium, the Netherlands, Luxemburg (Benelux) and Germany.
The new capital fund – Gilde Healthcare Services II – targets specialist clinics, elderly care, primary care, mental health, outsourcing services, medical product suppliers and other healthcare service providers.
“We are delighted with the fundraising of our second healthcare services fund and in particular to have the backing of a strong base of blue chip investors”, announced Jasper van Gorp, Managing Partner for Gilde Healthcare Services, last week. “We now have the capital available to support more private healthcare companies.”
The PE firm says that the closing of the fund comes at the right time as healthcare companies rely increasingly on private funds to finance their growth plans, because of diminishing government support and reluctant banks.
Gilde Healthcare invests in fast growing healthcare technology and healthcare services companies. It manages €550 million dedicated to innovative therapeutic and medical technology companies in Europe and the United States.
In the Netherlands the PE firm led the spin-off of the biotech company Viroclinics Biosciences from the Erasmus Medical Center. The Rotterdam-based Viroclinics is a leading diagnostic and clinical trial operation service company in the field of virology.
Last August Gilde Healthcare realized a successful exit on its 2013 investment in Eindhoven-based biotech company Sapiens SBS, which was acquired for approximately $200 million in an all-cash transaction by Medtronic.
Photo by Pieter van Marion (creative commons via Flickr)